Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.42 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880790 | 0.81 | KDM1A (0.35) | BACE1KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL5489557 | 0.79 | KMT2A (0.41) | BACE1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1445429 | 0.78 | BACE1 (0.43) | BACE1HCAR3HCAR2GPR35ALDH1A1 | |
| SCHEMBL5635402 | 0.78 | KMT2A (0.41) | KMT2ASMN1; SMN2MEN1LMNAPABPC1 | |
| SCHEMBL4482310 | 0.76 | HCAR2 (0.38) | BACE1HCAR2SMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL5637464 | 0.75 | KMT2A (0.40) | KMT2ASMN1; SMN2MEN1LMNAPABPC1 | |
| SCHEMBL23727532 | 0.75 | L3MBTL1 (0.36) | KMT2ASMN1; SMN2MEN1LMNAPABPC1 | |
| SCHEMBL257533 | 0.74 | BACE1 (0.49) | BACE1HCAR3HCAR2GPR35ALDH1A1 | |
| SCHEMBL6967453 | 0.73 | KMT2A (0.37) | BACE1HCAR3HCAR2GPR35KMT2A | |
| SCHEMBL12134101 | 0.73 | KMT2A (0.37) | BACE1HCAR3HCAR2GPR35KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158798-B2 | Coupling process for preparing quinolone intermediates | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-04-17 | — | — | US | disclosed |
| US-8158798-B2 | Coupling process for preparing quinolone intermediates | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-04-17 | — | — | US | disclosed |
| US-8039485-B2 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | WARNER CHILCOTT COMPANY, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039485-B2 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | WARNER CHILCOTT COMPANY, LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-7528264-B2 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528264-B2 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090111991-A1 | Coupling Process For Preparing Quinolone Intermediates | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111991-A1 | Coupling Process For Preparing Quinolone Intermediates | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2009-04-30 | — | — | US | disclosed |
| US-7456279-B2 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456279-B2 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | THE PROCTER & GAMBLE COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | THE PROCTER & GAMBLE COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | THE PROCTER & GAMBLE COMPANY (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232804-A1 | Coupling process for preparing quinolone intermediates | CYP3A4, CYP4B1, CYP4X1 | BACE1 3209/4885HCAR3 496/4885HCAR2 930/4885 |
| US-20090111991-A1 | Coupling Process For Preparing Quinolone Intermediates | CYP3A4, CYP4B1, CYP4X1 | BACE1 3209/4885HCAR3 496/4885HCAR2 930/4885 |
| US-20070232650-A1 | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | SLC25A11, MDH2, MDH1 | BACE1 4519/4885HCAR3 469/4885HCAR2 732/4885 |
| US-20070232806-A1 | Hydride reduction process for preparing quinolone intermediates | NQO1, NQO2, POR | BACE1 3085/4885HCAR3 744/4885HCAR2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.